By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the ...

Feb 3 (Reuters) - Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up ...

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a ...

Thus far, Pfizer's obesity efforts have crashed and burned. Last year, the pharmaceutical giant threw in the towel on ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Pfizer shares fell 3.3% Tuesday on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war ...

Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...

The new site is for people in the U.S. who are willing to pay out of pocket for certain brand-name medications, like Zepbound ...